Cargando…
Factor Xa inhibitors: critical considerations for clinical development and testing
The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor bearing cells and the interface of coagulation proteins, platelets, m...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122197/ https://www.ncbi.nlm.nih.gov/pubmed/33991266 http://dx.doi.org/10.1007/s11239-021-02455-x |